Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy

نویسندگان

  • Fumikata Hara
  • Sachiko Kiyoto
  • Daisuke Takabatake
  • Seiki Takashima
  • Kenjiro Aogi
  • Shozo Ohsumi
  • Norihiro Teramoto
  • Rieko Nishimura
  • Shigemitsu Takashima
چکیده

It is well-known that tamoxifen increases the risk of endometrial cancer. Although metastasis to the uterus from breast cancer is uncommon, there have been some case reports on uterine metastasis. If an endometrial abnormality is detected, the differential diagnosis of whether the uterine tumor is metastatic or primary is very important to determine the course of treatment. We herein report a case in which we detected a uterine tumor during follow-up after treatment with tamoxifen, and demonstrate that GCDFP-15 is useful in diagnosing metastatic uterine tumors arising from breast cancer.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases

Adjuvant endocrine therapy is an integral component of care for endocrine-dependent breast cancer. The aim of this type of therapy is to counteract the production and the action of estrogens. The ovary is the primary site of estrogen production in premenopausal women, whereas, in postmenopausal women, the main source of estrogens is adipose tissue. Therefore, ovarian function suppression is an ...

متن کامل

Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.

The recent past has witnessed the appearance of substantial data relating to endocrine therapy of breast cancer. In the adjuvant therapy setting in early breast cancer, several large, well-conducted, randomized, double-blind clinical trials have provided evidence for the value of the third-generation aromatase inhibitors (AI) anastrozole, exemestane, and letrozole. The three major studies to da...

متن کامل

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis

BACKGROUND Hormone receptor positive breast cancer is characterized by the potential for disease recurrence many years after initial diagnosis. Endocrine therapy has been shown to reduce the risk of such recurrence, but the optimal duration of endocrine therapy remains unclear. METHODS We conducted a systematic review and meta-analysis to quantify the benefits and harms of extended adjuvant t...

متن کامل

Value of sonographic endometrial findings in patients with breast cancer under tamoxifen therapy

Tamoxifen is utilized as adjuvant therapy in women diagnosed with breast cancer. In these patients, despite its positive risk/benefit ratio, tamoxifen may cause secondary effects on the endometrium, with increased risk of malignant diseases. So, the first question to be answered is: “Does tamoxifen increase the incidence of endometrial abnormalities?” The literature presents two meta-analysis-s...

متن کامل

ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy

PURPOSE Currently, although several clinical trials available give strong suggestions that extension of endocrine therapy has benefits, the risk level at which patients may benefit from extended endocrine therapy remains uncertain. This study aimed to identify the proportion of patients at a substantial risk of late recurrence after 5-year adjuvant endocrine therapy. PATIENTS AND METHODS We r...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 3  شماره 

صفحات  -

تاریخ انتشار 2010